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Abstract
Compounds that interact with microtubules, such as paclitaxel, have been shown to possess protective
properties against β-amyloid (Aβ)-induced neurodegeneration associated with Alzheimer's disease.
In this work, the novel agent (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]
oxazol-7a-yl)methanol was investigated for effectiveness in protecting neurons against several toxic
stimuli and its interaction with the microtubule network. Exposure of neuronal cultures to Aβ peptide
in the presence of 5 nM (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]
oxazol-7a-yl)methanol resulted in a 50% increase in survival. Neuronal cultures treated with other
toxic stimuli such as staurosporine, thapsigargin, paraquat and H2O2 showed significantly enhanced
survival in the presence of (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]
oxazol-7a-yl)methanol. Microtubule binding and tubulin assembly studies revealed differences
compared to paclitaxel, but confirmed the interaction of (3R,5S,7as)-(3,5-bis(4-fluorophenyl)
tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol with microtubules. Furthermore, in vitro
studies using bovine brain microvessel endothelial cells experiments suggest that (3R,5S,7as)-(3,5-
bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol can readily cross the blood-
brain barrier in a passive manner.
Introduction
It had previously been suggested that stabilization of microtubules by anti-mitotic drugs could
protect neurons from the toxic effects of β-amyloid (Aβ) peptide, a peptide believed to play a
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major role in the pathogenesis of Alzheimer's disease.1 Indeed, we reported a study in which
we demonstrated that microtubule stabilizing drugs such as taxanes, epothilones and
discodermolide had a protective effect against Aβ-induced degeneration of primary neurons
in culture.2 However, the success of a neuroprotective agent in vivo as a pharmaceutical product
depends on the ability of the compound to reach the site of action within the brain. There are
a variety of barriers to brain penetration including anatomical barriers, i.e., tight junctions,
reduced pinocytosis, and glycocalyx,3,4 metabolic barriers i.e. peptidases, and phase I and
phase II enzymes,5 and an electrostatic barrier due to sulfated glycoproteins at the cell surface.
Another major barrier to brain penetration is the existence of efflux transporters expressed at
the brain endothelium.6 If a drug is recognized as a substrate for one of these efflux transporters,
the permeation across the blood-brain barrier can be significantly compromised.7
In 1997, Shintani et al. reported that a small synthetic compound named GS-164, stimulated
microtubule assembly in vitro by a mechanism similar to that of paclitaxel.8 Under the
conditions used by us to prepare a sample of GS-164, a mixture of two diastereoisomers was
obtained, consisting of meso-compound (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-
oxazolo[3,4-c]oxazol-7a-yl)methanol (1), racemate (3R*,5R*)-(3,5-bis(4-fluorophenyl)
tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol (2) and (2-(4-fluorophenyl)
oxazolidine-4,4-diyl)dimethanol (3), an incomplete condensation product (Fig. 1). Based on
modeling studies, the authors had proposed that the R,R-enantiomer of compound 2 mimics
parts of the paclitaxel structure and is responsible for its paclitaxel-like activity. Our laboratory
has now separated the diastereoisomers present in GS-164 and has investigated the properties
of the (3R,5S,7as)-isomer 1 (Fig. 1). The compound exhibits neuroprotective properties when
tested with cultured neurons and passively permeates the blood-brain barrier. Interestingly,
although this compound binds weakly to microtubules, it does not show paclitaxel-like
microtubule stabilizing activity in vitro.
Results
Synthesis of 1
The reaction of p-fluorobenzaldehyde with tris(hydroxymethyl)aminomethane led to three
products (Fig. 1) that were separable by flash chromatography. Compounds 1, 2 and 3 were
produced in yields of 66%, 5%, and 21%, respectively. Single crystal X-ray diffraction was
used to determine the stereochemistry of 1 and 2 (Fig. 2). Thus the major product was the
3R,5S,7as meso compound 1. The 3R,5S,7ar meso compound, although a potential product,
was not formed. This is consistent with energy calculations.9
Microtubule Assembly and Stability
In the original article on GS-164 the authors concluded that the compound acted on tubulin in
a manner similar to paclitaxel.8 In addition, the authors used modeling to suggest that the 3R,
5R isomer was responsible for the paclitaxel-like activity. We have found that this isomer is a
minor product in the synthesis. We sought to determine whether the major product, the 3R,
5S,7as isomer 1 had paclitaxel-like activity. We first tested the ability of 1 to stimulate tubulin
assembly using microtubule protein (tubulin containing microtubule associated proteins) and
pure tubulin. Microtubule assembly was measured in two different ways, using a fluorescence
assay with microtubule protein without GTP (guanosine triphosphate), and a centrifugation
assay with pure tubulin plus GTP, and microtubule protein without GTP. Shown in Fig. 3 are
the results of the fluorescence assay. Compound 1 produced a small positive response (apparent
microtubule formation) at low concentrations, but the response did not increase with increasing
concentrations of 1. The maximum increase in fluorescence was about 20% of that produced
by paclitaxel. In the centrifugation assays, the amount of pelleted protein in the presence of
1 ranged from 10% to 20% of that formed in the presence of paclitaxel. Electron microscopic
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examination indicated some fibrous material in the presence of 1 indicating that the compound
induces aggregation of tubulin, but not microtubule formation. Similar results were obtained
with 2 and 3 (data not presented).
Paclitaxel is known to stabilize microtubules against cold-induced depolymerization. As
another means to compare the taxane and 1, we studied the cold-stability of microtubules
formed in vitro. Microtubules were formed from pure tubulin at 37 °C. Upon centrifugation,
81% of the protein was found in the pellet. When the sample was placed on ice for 15 min
before centrifugation only 8% of the protein was in the pellet fraction. The addition of 20 μM
paclitaxel to the microtubule suspension before the cold treatment stabilized the microtubules;
the pellet contained 79% of the protein. On the other hand, the addition of 400 μM 1 had no
effect on cold stability; 9% of the protein was found in the pellet. The results clearly
demonstrate that 1 does not possess the paclitaxel-like property of stabilizing microtubules
against cold-induced depolymerization.
Binding of 1 to Microtubules
With the use of tritiated compounds, the binding of 1 and paclitaxel to microtubules formed
from microtubule protein were measured (Fig. 4). Both compounds bound to microtubules in
a ratio of 7 to 8 nmol/mg protein. Since microtubule protein is about 70% tubulin, 1 mg
represents 0.7 mg of tubulin or 7 nmol. Thus, both compounds bind in about a one to one molar
ratio, but about 10-fold more 1 than paclitaxel was required to achieve maximum binding. To
determine whether the two compounds bind to the same site in tubulin, competitive binding
experiments were performed. Microtubules were formed in the presence of 100 μM [3H]-1 and
0 to 40 μM paclitaxel and in the presence of 20 μM [3H]-paclitaxel and 0 to 400 μM 1. Binding
of 20 μM paclitaxel was reduced 40% by 400 μM 1. Binding of 100 μM 1 was reduced 42%
by 40 μM paclitaxel. Thus, the two compounds appear to be weakly competitive of each other.
Protection of Primary Cortical Neurons Against Aβ Peptide and Cell-death Initiators
We and others have shown that exposure to Aβ induces beading, shortening, and eventual
disappearance of neuritic processes presumably due to disruption of the cytoskeletal network
and we have also found that paclitaxel protects against Aβ toxicity.10-12 Although 1 did not
have paclitaxel activity in vitro, it did protect primary cortical neurons exposed to toxic agents.
Protection against Aβ25-35 peptide is shown in Fig 5. The EC50 for 1 (concentration that lead
to a 50% increase in neuronal survival in the presence of the Aβ peptide) was 5 nM. The racemic
mixture 2 and the incomplete condensation product 3 had EC50 values of 50 nM and 40 nM,
respectively. Although the small toxic Aβ25-35 peptide was used in the majority of studies,
the observations were confirmed with exposure to Aβ1-42 peptide. Because 1 was the most
effective of the three compounds and was the major product in the synthesis, further studies
were restricted to this compound.
The effectiveness of 1 in protecting primary neurons against diverse toxic stimuli that lead to
cell death via various pathways was also investigated. 1 was added at a concentration of 100
nM approximately 2 h before the toxic stimuli, and cell viability was determined. As shown
in Fig. 6, exposure of the neurons to the Protein Kinase C inhibitor staurosporine, the
sarcoplasmic-endoplasmic Ca2+-ATPase inhibitor thapsigargin, and the oxidative stress-
inducing agent's paraquat and hydrogen peroxide all led to a 50% loss in neurons within 24 h.
In cultures treated with 1 before addition of the toxic stimuli, neuronal survival was
significantly enhanced and, in most cases, the percentage of live cells was nearly at control
levels. Thus the protective effect of 1 is not selective for the cell death pathway induced by
Aβ peptides but seems to be due to a more generalized cellular response that enables neurons
to withstand stressful conditions.
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Effects of 1 on Rhodamine 123 Uptake
Given the promising observations seen in the neuroprotective assays, additional studies were
performed to investigate the ability of 1 to cross the blood-brain barrier. The rhodamine 123
assay assesses the interaction of a compound with the efflux transporter P-glycoprotein, which
is expressed at the brain endothelium and can present a barrier to brain penetration. Paclitaxel
is a known substrate of P-glycoprotein (P-gp) and consequently has very minimal brain
penetration.13 Compound 1 was tested in the rhodamine 123 uptake assay using bovine brain
microvessel endothelial cells (BBMECs) grown in a 24-well plate. The uptake of rhodamine
123 was monitored in the presence of 1 at concentrations ranging from 1 μM to 50 μM. No
significant increase in rhodamine 123 was observed, except for the positive control,
cyclosporine A (CsA), a known substrate for P-gp (data not shown). These data suggest that
1 is not recognized as a substrate for the P-gp efflux transporter.
Permeability of 1
Bi-directional permeability studies were used to predict the brain permeation of 1 and to
determine if 1 permeates via an active or passive process. Compound 1 (10 μM) with trace
levels of [3H]-1 was added to the luminal or abluminal side of the BBMEC monolayer and
permeation was monitored for 1.5 h. During this time, permeation across the monolayer was
linear (r2 = 0.99) and all experiments were performed with n = 4. In the luminal to abluminal
direction, the Papp = 2.86 × 10-4 cm/sec. In the abluminal to luminal direction, the Papp =
2.44 × 10-4 cm/sec. This indicates that there is no statistical difference in permeability as a
result of direction. These data suggest that the permeability of 1 is a passive process since
permeation via an active process would yield directional differences in permeability.
To confirm that permeation of 1 is indeed a passive process, the permeability of 1 (10 μM)
with trace levels of [3H]-1 was investigated in the luminal to abluminal direction at
temperatures ranging from 4 °C to 37 °C over 1.5 h to generate an Arrhenius plot (Fig. 7). The
activation energy calculated from the slope of the Arrhenius plot was 26.3 kJ/mol, which is
suggestive of a passive process since carrier-mediated processes typically fall within a range
of 29-105 kJ/mol.14
Discussion
Following the report by Shantani et al.8 that GS-164 promoted the assembly of tubulin and
stabilized microtubules in vitro, we sought to test the ability of the compound as a
neuroprotective agent. When we tested the three products of GS-164 synthesis we could not
find evidence that any of them promoted the assembly of tubulin. We did find that 1, the R,S
stereoisomer of GS-164, binds to microtubules in a molar ratio of about one 1/tubulin molecule.
However, it binds with an apparent affinity that is about 10% that of the affinity of paclitaxel
and appears to be only partially competitive with the taxane. Moreover, 1 did not stabilize
microtubules in vitro. In spite of these differences, 1, like paclitaxel, has excellent
neuroprotective properties against Aβ and other toxic stimuli. Since 1 must be able to cross
the blood-brain barrier to exert its neuroprotective effects in neurodegenerative diseases, the
potential for 1 to penetrate the blood-brain barrier was thoroughly investigated using in vitro
methodologies. In vitro studies performed using BBMECs as a model of the blood-brain barrier
indicated that 1 had excellent potential for brain penetration. The physiochemical properties
of 1 make it a potential candidate for use as a CNS drug. Compared to paclitaxel, 1 has a much
lower molecular weight, possesses halogen groups that promote passive diffusion15 and is not
a substrate for any of the efflux transporters expressed at the brain endothelium. All of these
features are important in determining whether a drug will be able to cross the blood-brain
barrier and reach a site of action within the brain.7,15,16
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The observation that 1 protects neurons against Aβ toxicity is similar to what we have found
with known microtubule-stabilizing drugs such as paclitaxel.2,10,17 The in vitro studies suggest
that 1 interacts with microtubules differently than paclitaxel does. Exposure to 1 led to the
preservation of the cytoskeletal integrity in primary neurons exposed to Aβ. Our previously
published work using calcein labeling demonstrated that Aβ leads to the actual loss of neurites
and not just a loss of tubulin labeling.2,10,17 The neuritic dystrophy attests to the complexity
of the signaling events involved in the neuronal response to Aβ and suggests that 1 may be
acting on a different pathway than paclitaxel in leading to preservation of the neurites.
Furthermore, though it is reasonable to assume that paclitaxel ultimately protects neurons by
stabilizing microtubules, the cellular mechanism may be more complex, possibly involving
unique effects on specific signaling pathways. For example, we have found that paclitaxel
prevents the Aβ-induced activation of Cdk5, one of the proline kinases strongly implicated in
the abnormal phosphorylation of the Tau protein found in tangles in Alzheimer's disease brain.
18
Diverse experimental approaches have provided strong evidence that dysregulation of Ca2+
homeostasis is a driving force for neuronal death in neurodegenerative diseases19 and paclitaxel
was shown to protect neurons against Ca2+ influx,20 against glutamate-induced excitotoxicity,
21 and against Thapsigargin-induced endoplasmic reticulum stress and dysfunction,12 among
other toxic insults. It is not yet known how this occurs, but specific Ca2+ signaling pathways
may be sensitive to the state of the cytoskeletal network in neurons. Agents as structurally
different as paclitaxel and 1 could modulate very different Ca2+ signaling cascades in intact
cells. Although 1 does not mimic paclitaxel in vitro, this agent apparently activates unique
protein interactions and signaling cascades that ultimately leads to the preservation of neuritic
processes. As previously suggested,22 the state of the neuronal cytoskeleton may serve as a
surveillance system that transduces multiple types of stress signals. Agents that invoke
mechanisms that slow or prevent the neuritic dystrophy initiated by such signals give the
neurons a chance to mobilize other defenses and thereby enhance their survival. Experimental
strategies designed to delineate, at the molecular level, the mechanisms through which agents
such as 1 and paclitaxel activate protective signaling cascades may well provide opportunities
for innovative therapeutic interventions that capitalize on these targets.
Experimental Section
Chemistry. Analytical Characterization—1H, 13C NMR spectra were recorded on a 400
MHz NMR instrument (400 and 100 MHz respectively) spectrometer. High-resolution mass
spectra (HRMS) were obtained on a ZAB double-focusing mass spectrometer. IR spectra were
recorded on a FTIR instrument. Melting points are uncorrected. Column chromatography was
performed employing silica gel (230-400 mesh). The purities of 1 and 2 were determined by
HPLC and were and found to be >95% pure. X-ray diffraction data were collected on a ccd
area detector using graphite-monochromated Mo Kα radiation (λ = 0.71073 Å). See
supplemental data for additional information.
Synthesis of 1—A suspension of p-fluorobenzaldehyde (27 g, 0.22 mol) and tris
(hydroxymethyl)aminomethane (13 g, 0.11 mol) in toluene (350 mL) was heated at reflux
temperature for 12 h with azeotropic removal of water. The reaction mixture was concentrated,
stirred at room temperature and the precipitated unreacted p-fluorobenzaldehyde was removed
by filtration. The residue obtained after removal of solvent was subjected to flash
chromatography on silica gel using hexane:ethylacetate (4:1 and 1:1). Crystallization of the
respective fractions afforded pure compounds (1, 2 and 3) in yields of 66%, 5%, and 21%,
respectively. The structures of the products were assigned by spectral data and the relative
stereochemistry of 1 and 2 was assigned from single crystal X-ray diffraction data.
Desino et al. Page 5














methanol (1)—Crystallized from hexane as a colorless crystalline solid; mp. 90 °C; IR υ
cm-1 3444, 2873, 1606, 1504, 1222, 1153, 1078, 1006, 837; 1H NMR (CDCl3) δ 3.50 (br s,
2H), 3.94 (d, J = 8.9 Hz, 2H), 4.05 (d, J = 8.9 Hz, 2H), 5.55 (s, 2H), 7.07 (m, 4H), 7.44 (m,
4H); 13C NMR (CDCl3) δ 65.63, 72.66, 74.89, 96.65, 115.41, 115.58, 128.55, 128.62, 135.26,
135.29, 161.95, 163.91; HRMS (FAB+) m/z calculated for C18H18NO3F2 [M+H] 334.1255
found 334.1230.
(3R*,5R*)-(3,5-bis(4-Fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)
methanol (2)—Crystallized from hexanes/CH2Cl2 as a colorless crystalline solid; mp. 115 °
C; IR υ cm-1 3440, 2870, 1606, 1512, 1427, 1384, 1226, 1155, 1076, 837; 1H NMR (CDCl3)
δ 3.75 (m, 2H), 3.84 (d, J = 8.8 Hz, 1H), 3.88 (d, J = 8.9 Hz, 1H), 4.10 (d, J = 8.9 Hz, 1H),
4.20 (d, J = 8.8 Hz, 1H), 5.16 (s, 1H), 5.51 (s, 1H), 6.89 (m, 6H), 7.27 (m, 2H); 13C NMR
(CDCl3) δ 65.60, 72.12, 74.87, 93.03, 93.91, 115.14, 115.31, 115.35, 115.52, 115.78, 129.21,
129.29, 129.34, 129.42, 130.21, 130.24, 135.87, 135.90, 161.89, 164.34; HRMS (FAB+) m/z
calculated for C18H18NO3F2 [M+H] 334.1255 found 334.1237.
(2-(4-Fluorophenyl)oxazolidine-4,4-diyl)dimethanol (3)—Crystallized from
isopropanol as a colorless crystalline solid; mp. 89 °C; IR υ cm-1 3450, 2877, 1604, 1512, 1420,
1296, 1228, 1157, 1047, 837; 1H NMR (CDCl3) δ 3.58 (m, 3H), 3.71 (m, 2H), 3.85 (d, J = 8.6
Hz, 1H), 5.41 (s, 1H), 7.06 (m, 2H), 7.44 (m, 2H); 13C NMR (CDCl3) δ 64.57, 64.98, 67.62,
70.73, 91.79, 115.81, 116.02, 128.29, 128.37, 134.91, 162.17, 164.63; HRMS (FAB+) m/z
calculated for C11H15NO3F [M+H] 228.1036 found 228.1036.
Microtubule Assembly Assay—Microtubule protein (tubulin preparation containing
microtubule-associated proteins, (MAPs) was obtained from bovine brain.23 Pure tubulin was
isolated from microtubule protein by a previously described procedure.24 Microtubule
assembly in vitro was measured using two different assays. One assay takes advantage of the
fact that 4′,6-diamidino-2-phenylindole (DAPI) binds to microtubules producing an increase
in fluorescence.25 The reactions were performed in 96-well plates in a volume of 120 μL per
well. The wells contained PEM buffer (0.1 M Pipes, 1 mM MgSO4, 1 mM EGTA, pH 6.9),
4% DMSO, 10 μM DAPI, 2 mg/mL microtubule protein, and varying concentrations of
paclitaxel or 1. The plates were incubated at 37 °C for 30 min after which the fluorescence was
measured in a multi-plate reader. The readings were corrected for a control lacking either
compound. A centrifugation assay was also employed in which microtubules are pelleted after
the assembly reaction (data not shown).26
Microtubule Binding Assay—Binding of 1 and paclitaxel to microtubules was measured
using tritiated compounds. [3H]-Paclitaxel was purchased from Moraveck Biochemicals, Inc.,
Brea, CA and 1 was tritiated by ViTrax Co., Placentia, CA. Solutions (100 μL) of 2 mg/mL
microtubule protein in PEM buffer containing 0.5 mM GTP and various concentrations of
[3H]-1 (1 × 105 cpm/nmol) or [3H]-paclitaxel (9 × 104 cpm/nmol) in Beckman TLA-100
centrifuge tubes were incubated at 37 °C for 10 min. Microtubule pellets were collected by
centrifugation at 100,000 × g for 4 min. The pellets were dissolved in 0.1 M NaOH and
radioactivity and protein concentrations were determined.
Neuronal Cell Culture—To prepare the primary neurons, dissociated cortical cell cultures
were established from embryonic day 18 rat fetuses recovered from pregnant Sprague Dawley
rats (Harlan Sprague Dawley, Inc., Indianapolis, IN).27 After the final precipitation step,
neurons were suspended in fresh DMEM/F12 (Sigma Chemical Co. St. Louis, MO) with 10%
fetal bovine serum (Atlanta Biologicals, Atlanta, GA) and plated at a density of 2.5 × 105 cells
in 35 mm glass bottom microwell dishes (Mat-Tek Co., Ashland, MA), coated with poly-D-
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lysine. Serum-containing medium was removed after 24 h, and the cells were maintained in
serum-free DMEM/F12 containing the N2 supplements. Cultures were grown at 37 °C in 5%
CO2 and 97% humidity as described.27
Treatment with Aβ Peptide and Cell-death Initiators—After five days in culture, the
primary neurons were exposed to either Aβ25-35 or Aβ1-42 in the presence or absence of
concentrations of 1 ranging from 0.5 nM to 60 nM. 1 was added approximately 2 h before the
Aβ peptides. The Aβ25-35 was synthesized and purified in the Biochemical Research Services
Lab at The University of Kansas. The reverse sequence peptide used as a control, Aβ35-25,
and the Aβ1-42 peptide used in confirmatory experiments were purchased from Bachem
(Torrance, CA). Prior to the addition of the peptides to the cultures, the Aβ peptide stocks (1.3
mg/ml) were diluted into 10 mM Tris/Cl, pH 7.4, and maintained at 37 °C for 24 h. Each batch
of Aβ peptide was analyzed for β-sheet formation by circular dichroism, but no attempt was
made to separate oligomers from fibrils. The peptides were added directly to the culture
medium, at a final concentration of 10 μM. Control cultures received the DMSO vehicle alone,
and the final concentration of DMSO never exceeded 0.04%. Assays were carried out 48 h
following Aβ peptide addition. The effects of neurotoxic stimuli other than Aβ peptides were
also used to assess the protective effect of 1 against various cell-death initiators. Neurotoxic
stimuli included staurosporine (100 nM) to induce apoptosis, thapsigargin (100 nM) to cause
ER stress, and paraquat (25 μM) or hydrogen peroxide (25 μM) to induce oxidative stress. All
reagents were obtained from Sigma Chemical Co., St Louis, MO.
Measurement of Cell Viability—The effects of the Aβ peptides and 1 were determined by
monitoring neuronal cell survival using the Live/Dead assay as previously described.2,10
Following exposure to the peptides and other compounds, cells were labeled with 20 μM
propidium iodide (PI) and 150 nM calcein acetoxy-methylester (Molecular Probes, Eugene,
OR) for 30 min at 37 °C, rinsed with phosphate buffered saline (PBS) and visualized under a
Nikon inverted microscope (Nikon Eclipse TE200, Japan) with filters for fluorescein-
isothiocyanate and Texas Red. Digital images were captured and the number of viable (green)
and dead (red) neurons was determined by counting the cells in 6-12 microscopic fields per
culture dish in duplicate dishes for each treatment. All experimental treatments were carried
out on at least two separate embryonic neuronal preparations with approximately 1500 neurons
scored under each treatment condition. The raw data from each experiment were combined
and the significance of differences between cultures exposed to various treatments was
determined as described using Student's t test.2 Neuronal survival in the untreated control
samples was considered to represent maximal viability and survival in the Aβ-only samples
represents minimal viability.
Isolation and Cell Culture of Brain Endothelial Cells—BBMECs were isolated from
the gray matter of bovine cerebral cortices by enzymatic digestion followed by centrifugation
as described.28 Isolated BBMECs were seeded at a density of approximately 50,000 cells/cm2
onto 24-well culture plates or 100 mm culture dishes as previously described.29
Rhodamine 123 Uptake Assay—In this assay, rhodamine 123 is used as a surrogate P-
glycoprotein (P-gp) substrate.30 The effect of the test compound on rhodamine 123 is
determined by monitoring intracellular fluorescence. If the test compound is a substrate for P-
gp, then addition of the compound will increase rhodamine 123 uptake relative to the negative
control. BBMECs were seeded onto 24-well culture plates and used to assay for P-gp
interaction as.29 Briefly, BBMECs were rinsed with warm PBSA (phosphate buffered saline
containing CaCl2, MgSO4, glucose and L-ascorbic acid) and allowed to acclimate for 10 min.
The PBSA was removed and solutions of 1 (1 μM- 50 μM) were added to the wells and allowed
to incubate for 30 min at 37 °C. Rhodamine 123 was then added to all wells at a concentration
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of 5 μM and cells were incubated for an additional 2 h. After the incubation, cells were quickly
rinsed with ice cold PBS several times. Lysis buffer (0.5% v/v Triton X-100 in 0.2 M NaOH)
was then added to all wells and allowed to solubilize cells for at least 30 min. Aliquots (200
μL) were taken from all wells to determine rhodamine 123 concentration and 10 μL aliquots
were removed from all wells to determine the protein concentration using a Pierce BCA Protein
Assay Kit (Pierce, Rockford, IL).
BBMEC Permeability Assays—BBMECs were grown on 0.4 μm Nucleopore(R)
polycarbonate membranes in a 100 mm culture dish coated with rat tail collagen and
fibronectin. Once cells had formed a confluent monolayer as determined by light microscopy,
the membranes were transferred to Side-Bi-Side™ diffusion chambers as previously described
by.31,32 Briefly, each chamber was filled with 3 mL of PBSA and either the luminal (blood)
or abluminal (brain) donor chambers contained 10 μM of unlabeled 1 and a trace amount of
[3H]-1. The temperature was maintained at 37 °C within the chamber with an external
circulating water bath and chamber contents were stirred with Teflon(R) coated magnetic stir
bars driven by an external console. At various time points up to 90 min, 200 μL aliquots were
removed from the receiver side and 20 μL aliquots of the donor solution were taken at time
zero. The integrity of the cell monolayer was tested post experiment by monitoring the
permeability of [14C]-sucrose, a low permeability paracellular marker that should not readily
cross the cell monolayer. All samples were analyzed by liquid scintillation counting. For
temperature dependent permeability studies BBMECs were grown on 0.4 μm Nucleopore(R)
polycarbonate membranes then transferred to Side-Bi-Side™ diffusion chambers as described
above. 1 (10 μM) with trace amounts of [3H]-1 was added to the luminal chambers and 200
μL samples were taken from the abluminal chamber at various time points up to 90 min. The
apparent permeability of 1 was calculated at a range of temperatures from 4 °C to 37 °C. An
Arrhenius plot was generated to determine the activation energy of transport. The integrity of
the cell monolayer was tested post experiment by monitoring the permeability of [14C]-sucrose
and samples were analyzed by liquid scintillation counting.
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Abbreviations
Aβ β-amyloid
BBMEC bovine brain microvessel endothelial cells
CsA cyclosporine A
DAPI 4′,6′-diamino-2-phenylindole




PBS phosphate buffered saline
PBSA phosphate buffered saline with ascorbic acid
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Reaction scheme for the synthesis 1. Additional products are 2 and 3.
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Structures and ellipsoid drawings of meso diastereoisomer (3R,5S,7as)-1 and (3R*,5R*)-2)
from X-ray diffraction.
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Stimulation of microtubule protein assembly by paclitaxel (top) and 1 (bottom) as determined
by monitoring the increase in DAPI fluorescence. Microtubule protein (2 mg/mL) was
incubated in PEM buffer containing 10 μM DAPI and varying concentrations of paclitaxel or
1 in 96-well plates for 30 min at 37 °C. Maximum fluorescence is that which is achieved by
25 μM paclitaxel.
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Binding of paclitaxel (top) and 1 (bottom) to microtubules. Microtubules were formed from
microtubule protein (2 mg/mL) and incubated with different concentrations of 3H-paclitaxel
or 3H-1 for 10 min at 37 °C. The microtubules were collected by centrifugation and dissolved
in 0.1 M NaOH. Protein concentrations and radioactivity measurements were then determined.
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Dose dependent effects of 1 on survival of primary cortical neurons exposed to the toxic β-
amyloid (Aβ) peptide for 48 h. The percentage of neurons surviving was determined by the
Live/Dead assay. Data are from six randomly selected fields from two neuronal preparations
(n ∼1,500 cells/condition). Statistical significance was determined by Students t test (# =
p<0.001 for controls versus Aβ only). ** = p<0.001 for Aβ only versus Aβ + drug.
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Effects of 1 on toxicity induced by diverse stimuli. Primary neurons were exposed to 100 nM
staurosporine (Str), 100 nM thapsigargin (Tg), 25 μM paraquat (PQ), or 25 μM H2O2 ± 100
nM 1. Mean percent survival was determined 24 h later, and statistical significance was
assessed using Student's t test (*= p<0.05 and **= p< 0.005 for each toxic stimulus alone versus
the toxic stimulus plus the drug). Data are from ∼1,000 cells per condition.
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Arrhenius plot of the apparent permeability coefficients (Papp) of 1 in bovine brain microvessel
endothelial cells at temperatures ranging from 4 °C to 37 °C over 1.5 h. Data ±SD, n = 4.
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